Skip to main content
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc. — Investor Relations & Filings

Ticker · SER ISIN · US00848H1086 LEI · 5493005PJ4B0GQ36ED85 US Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country US United States of America
Listing US SER

About Serina Therapeutics, Inc.

https://serinatherapeutics.com/

Serina Therapeutics, Inc. is a biotechnology company that develops novel therapeutics based on its proprietary POZ platform technology. This platform utilizes advanced polyoxazoline (POZ) polymers to create drug delivery systems for small molecule drugs, aiming to improve their therapeutic properties, safety, and efficacy. The technology is designed for programmable and targeted drug delivery to optimize treatments. The company's development pipeline is focused on addressing unmet medical needs in neurological diseases, including Parkinson's disease, as well as pain, cancer, and inflammation. Serina Therapeutics aims to redefine the standard of care by enhancing the performance of new and existing drug candidates.

Recent filings

Filing Released Lang Actions
S-3
Regulatory Filings Classification · 85% confidence The document is a Form S-3 Registration Statement under the Securities Act of 1933 filed with the U.S. SEC, containing the preliminary prospectus for resale of shares by selling stockholders. It is not an earnings release, management discussion, capital financing update per se, or a proxy/AGM document, but rather a formal regulatory compliance filing to register securities. Therefore it falls under the general regulatory filings category (RNS).
2026-05-22 English
8-K
Regulatory Filings Classification · 85% confidence The document is a US SEC Form 8-K “Current Report” under the Exchange Act that merely furnishes a press release of quarterly results as an exhibit (Item 2.02), without containing the actual earnings data or detailed financial statements. It is an SEC regulatory filing rather than the earnings release itself or a full financial report. Therefore it falls under the general Regulatory Filings category (RNS).
2026-05-14 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
10-K/A - Serina Therapeutics, Inc. (0001708599) (Filer)
Annual Report FY 2025
2026-03-27 English
S-8 - Serina Therapeutics, Inc. (0001708599) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Serina Therapeutics, Inc. It registers additional shares under the company's 2024 Equity Incentive Plan. The document includes legal and procedural information related to the registration of securities, exhibits, consents, and signatures of company officers and directors. It is not a financial report, earnings release, proxy statement, or any other type of report but a registration statement for securities issuance under an employee benefit plan. Form S-8 filings are specifically related to securities registration for employee benefit plans and do not fit into other categories like Annual Report, Earnings Release, or Proxy Solicitation. Therefore, the correct classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-03-25 English
10-K - Serina Therapeutics, Inc. (0001708599) (Filer)
Annual Report FY 2025
2026-03-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.